Incyte Corporation

This study tested a drug called itacitinib combined with steroids as a first treatment for moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. It included 155 participants who had received a stem cell transplant. The study wa…

This study tested a drug called itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a lung condition that causes scarring and breathing problems) after a double lung transplant. The goal was to see if the drug was safe and could improve lung function. The stu…

This study tested a combination of two drugs, tafasitamab and parsaclisib, in adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal was to see if the combination was safe and effective. The trial was terminated early, but data on side e…

This study tested whether adding a new drug called parsaclisib to the standard treatment ruxolitinib could help people with myelofibrosis whose spleens and symptoms were not improving enough on ruxolitinib alone. The trial aimed to see if the combination could shrink the spleen a…

This study tested a new drug called INCB059872 in people with Ewing sarcoma that had returned or stopped responding to standard treatments. The goal was to see if the drug is safe and if it can shrink tumors. The trial was stopped early, so results are limited.